(NASDAQ: IRWD) Ironwood Pharmaceuticals's forecast annual revenue growth rate of 6.52% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.68%.
Ironwood Pharmaceuticals's revenue in 2023 is $432,381,000.On average, 4 Wall Street analysts forecast IRWD's revenue for 2023 to be $69,042,606,077, with the lowest IRWD revenue forecast at $68,400,135,053, and the highest IRWD revenue forecast at $69,945,812,608. On average, 3 Wall Street analysts forecast IRWD's revenue for 2024 to be $71,978,612,787, with the lowest IRWD revenue forecast at $71,819,361,160, and the highest IRWD revenue forecast at $72,287,748,298.
In 2025, IRWD is forecast to generate $82,993,516,982 in revenue, with the lowest revenue forecast at $78,581,310,142 and the highest revenue forecast at $91,647,750,002.